Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Elderly lymphoma patients may benefit from Geriatric-Guided support

NCT ID NCT07476105

Symptom relief Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding geriatric-guided care—including nutritional and physical therapy support—improves quality of life for elderly patients with diffuse large B-cell lymphoma. About 170 patients aged 70 and older who are unfit or frail will receive either this extra support or standard care alongside their chemotherapy. The goal is to see if the personalized approach helps them tolerate treatment better and feel better overall.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Geriatric-guided supportive care (structured geriatric consultation, nutritional and physiotherapy evaluation)
What this could lead to
If successful, this approach could improve quality of life and treatment tolerance for elderly lymphoma patients.
What could go wrong
This is a non-randomized trial with only 170 participants, so results may not apply broadly. The intervention is supportive, not a direct treatment for the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 170 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

70 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of DLBCL or Follicular Lymphoma (FL) grade IIIB. 2. Age ≥ 70 years. 3. UNFIT or FRAIL status according to sGA evaluated by the onco-hematologist at baseline. 4. Patients eligible to a curative intent standard first line chemoimmunotherapy. 5. Ability to understand and willingness to comply with study procedures. 6. Signature of a written informed consent. Exclusion Criteria: 1. Patients not meeting at least one of the inclusion criteria listed above. 2. Refuse to sign a written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffuse large B cell lymphoma Follicular lymphoma grade 3B

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    24 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O.R.N. S. Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico

    Avellino, Italy

  • A.O.U. Careggi - S.O.D. Ematologia

    Florence, Italy

  • A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia

    Torino, Italy

  • A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia U

    Torino, Italy

  • A.O.U. Policlinico "Paolo Giaccone" - U.O.C. Ematologia

    Palermo, Italy

  • A.O.U. Senese - U.O.C. Ematologia

    Siena, Italy

  • A.O.U.I. di Verona - U.O.C. Ematologia

    Verona, Italy

  • A.R.N.A.S. "Brotzu" P.O. Businco - S.C. Ematologia e TMO

    Cagliari, Italy

  • A.S.L. Teramo Osp. "Giuseppe Mazzini" - U.O.S. Ematologia

    Teramo, Italy

  • A.S.S.T. Grande Ospedale Metropolitano Niguarda - S.C. Ematologia

    Milan, Italy

  • A.S.S.T. Spedali Civili - S.C. Ematologia

    Brescia, Italy

  • A.S.U. Friuli Centrale - Clinica Ematologica

    Udine, Italy

  • A.U.S.L. I.R.C.C.S. Arcispedale S. Maria Nuova - S.C. Ematologia

    Reggio Emilia, Italy

  • A.U.S.L. di Piacenza Osp. Guglielmo da Saliceto - U.O.C. Ematologia e Centro Trapianti

    Piacenza, Italy

  • A.U.S.L. di Ravenna Osp. S. Maria delle Croci - U.O.C. Ematologia

    Ravenna, Italy

  • Azienda Ospedaliero Universitaria delle Marche - S.O.D. Clinica Ematologica

    Ancona, Italy

  • Azienda Ospedaliero Universitaria di Parma - S.C. Ematologia e C.T.M.O.

    Parma, Italy

  • Azienda USL Toscana Centro - SOS Oncoematologia

    Prato, Italy

  • Fondazione Policlinico Campus Bio-Medico - U.O.C. Ematologia e trapianto di cellule staminali

    Roma, Italy

  • I.R.C.C.S. Centro di Riferimento Oncologico - S.O.C. Oncologia medica e dei tumori immuno-correlati

    Aviano, Italy

  • I.R.C.C.S. Fondazione Cà Granda Ospedale Maggiore Policlinico - S.C. Ematologia

    Milan, Italy

  • I.R.C.C.S. Fondazione San Gerardo dei Tintori - S.C. Ematologia

    Monza, Italy

  • I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. Oncologia 1

    Padova, Italy

  • I.R.C.C.S. Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia

    Bari, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.